ROCKVILLE, Md.--Human Genome Sciences announced last week that it successfully completed phase I clinical studies of its second genomics-derived drug. Keratinocyte growth factor-2 (KGF-2) is a therapeutic protein being evaluated as a treatment for wound-healing. Successful phase I studies of Myeloid progenitor inhibitory factor-1 were announced last month. The drugs are the first two therapeutic products discovered using genomic techniques to enter clinical trials, the company claimed. CEO William Haseltine said HGS could now be called "a pioneer in genomic drug development as well as in genomics."
HGS Completes Phase I Study of Its Second Genome-Based Drug
Nov 14, 1998